Tag: Southwest

  • New federal cannabis research center launches (Newsletter: April 25, 2025)

    Rhode Island regulators will consider hemp issues on Friday. Oklahoma regulators will host an event on marijuana legislation and enforcement on June …

  • Regulatory chaos threatens US hemp industry

    Regulatory chaos threatens US hemp industry

    The U.S. hemp-derived cannabinoid market has swelled in total value, but the industry continues to face serious threats from a messy patchwork of state bans and regulations that are stunting growth and pushing production overseas, according to a leading cannabis economist.

    “All this hysteria over cannabinoids is having a profound effect on the fiber and grain environment,” said Beau Whitney, founder of Whitney Economics, told Green Market Report in an interview.

    Whitney’s analysis shows the hemp market, including CBD, THC, CBN, CBG and related compounds, has grown into a robust industry that now rivals legal marijuana markets. Two years ago, his firm calculated the total market for hemp-derived cannabinoids ranged from $21.3 billion to $35.8 billion, with a midpoint of $28.4 billion.

    Of that total market, Whitney noted that “about $21 billion was available on the legal side and then about $7 billion was on the illicit side.”

    Recent surveys conducted by Whitney in states, including Arizona, Illinois, Tennessee and Texas, validated these projections. “In states where I could get data and states that allowed for the sales, that’s where (the data is) really solid,” Whitney said. “They’re being confirmed as being conservative.”

    While it isn’t an apples-to-apples comparison, since Whitney’s measuring total market potential for hemp against only legal sales in the marijuana world, the economist said it’s becoming nearly impossible to measure legal hemp sales accurately as state regulations constantly shift.

    “Every time I turn around, a different state has a different proposal to ban all of this,” Whitney said.

    As a result, Whitney’s firm focuses on measuring total market potential rather than solely legal sales. Still, he sees potential growth beyond current projections, especially with hemp-derived cannabis beverages making a splashy entrance to the market.

    “Hemp-derived cannabis beverages, Delta-9 beverages, are coming on in a big way,” he said, noting these products are breaking out of traditional CBD shops and into “bars, liquor stores, restaurants and grocery stores.”

    According to Whitney, legislative approaches to hemp cannabinoids have had unintended consequences across the broader hemp industry. The confusion also affects hemp fiber and grain sectors that have nothing to do with intoxicating products.

    “Banks are debanking hemp fiber and hemp grain companies,” Whitney claimed. “Investors are pulling back on investment into the infrastructure.”

    Whitney calculated that “the lost economic potential because of these legislatures was between $20 (billion) and $25 billion dollars.” He added that he’s “taken (his) acreage forecast through 2030 down by over 4 million acres.”

    Whitney estimated “an impact to farmers of between $1 (billion) and $3.5 billion in revenue” in lost opportunities.

    Licensed hemp acreage plummeted from 525,000 acres in 2019 to just 30,000 acres last year. That decline means there isn’t enough domestic acreage to support the hemp cannabinoid industry, potentially pushing manufacturing overseas.

    “It’s driving manufacturers to China and to South America and Canada and anywhere else that can get CBD or CBD biomass,” Whitney said, which creates additional public safety risks as “Chinese CBD is laden with heavy metals.”

    He said that the irony is that policies ostensibly designed to protect public safety might actually be increasing risks. “The whole legislative goal of having increased public safety … all their policies are running against that, and they’re actually increasing the public safety risk rather than decreasing it.”

    Whitney has long advocated for product-level regulation rather than wholesale bans, suggesting age restrictions, testing requirements and proper labeling would be sufficient, “if it’s intoxicating.”

    “That’s all you need to do,” he said.

    Additionally, current regulatory approaches, he argued, are creating a false binary.

    “The dispensary model for marijuana is failed. It’s an abject failure because it’s limiting people’s access,” he said. “Not everybody wants to go in there.”

    Whitney also noted that declining commodity prices for corn, wheat, soybeans and other staple crops have driven farmers to seek higher-revenue alternatives. Hemp represents not only potential increased revenue per acre but also agricultural benefits – if the industry is actually allowed to develop.

    “Hemp is a great rotational crop because it helps with the soil, it restores certain aspects of the soil, and it takes impurities out of the soil,” Whitney explained. He added that using hemp in rotation can increase output for subsequent soybean crops “on a significant per bushel level.”

    Despite the challenges, Whitney still forecasts potential growth, projecting “a million acres in 2030, which is twice the size of it at its peak.”

    Many have attributed much of the regulatory confusion to federal inaction, particularly from the FDA, which has taken a hands-off approach and created much of the uncertainty. Whitney expressed hope that the upcoming farm bill might provide greater clarity, though he noted the legislation “has been pushed out a number of times.”

    The post Regulatory chaos threatens US hemp industry appeared first on Green Market Report.

  • Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts

    Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts

    Florida-based Fluent Corp. (CSE: FNT.U) (OTCQB: CNTMF) posted a $40.3 million net loss for the 2024 calendar year against $103.5 million in net revenues, the company reported on Thursday after U.S. markets closed.

    The annual loss was up 78% year-over-year from the $22.7 million net loss reported in 2023, which CEO Robert Beasley didn’t bother addressing in a press release.

    Rather, Beasley said the company is “positioning ourselves for continued success in the year ahead,” with the acquisition of RIV Capital in New York last year, followed by a rebranding from Cansortium to Fluent Corp., the launch of several new product lines and other expansion efforts that he said are already bearing fruit.

    Beasley also denied that the failure of recreational marijuana legalization at the ballot box last fall in Florida had a significant impact on the company’s business plans, but admitted the company’s been “somewhat impacted by broader industry dynamics.”

    “Many in the sector had prepared extensively for the amendment’s passage, and its delay has created market challenges, such as oversupply, heightened competition and increased product discounting,” Beasley said.

    For the fourth quarter, which ended on Dec.31, 2024, Fluent reported a year-over-year revenue downturn to $24.9 million from $25.5 million. For the full year, however, revenues were up 6.4% to $103.6 million from $97.3 million.

    In the final quarter of the year, Fluent also reported an impairment of intangible assets of $64.3 million, which it said was related to a license in Florida and “reduces the carrying value of the Company’s intangible assets on its consolidated statements of financial position to $37.6 million.”

    Fluent currently operates 42 dispensaries in Florida, New York, Pennsylvania and Texas, and said it expects to open at least three more in 2025. The company also expects to finish construction at a new cannabis cultivation facility in Tampa Bay by the end of the second quarter, which will add another 7,000 square feet of canopy to its production capacity.

    The company recently refinanced a $71 million loan from Chicago Atlantic that had been set to mature in May and inked a new $96.5 million credit line with the firm.

    At the end of December, Fluent had $61.4 million in total assets, including $40.1 million in cash, against $215.9 million in total liabilities.

    The post Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts appeared first on Green Market Report.

  • 4Front Ventures delays annual filings, can’t pay auditors

    4Front Ventures delays annual filings, can’t pay auditors

    4Front Ventures (CSE: FFNT) (OTCQB: FFNTF) said Wednesday it can’t meet its April 30 regulatory deadline to file its annual financial report because it can’t pay its auditors.

    The Phoenix-based company also applied for a management cease trade order that would temporarily restrict company leaders from trading its securities while it tries to fix its money problems.

    The delay comes as the company works to “resolve the issue and expects to be able to file the necessary reports upon completion of securing additional financing, restructuring its liabilities and continuing discussions with one of the company’s lessors,” according to a news release. Management stated that it expects to file within 60 days of restarting its audit.

    The delay follows a tough stretch for 4Front, which lost $6.4 million in the third quarter while watching its revenue slide. Third-quarter revenue dropped to $15.2 million, down from $20.1 million a year earlier and lower than the $18.7 million from the previous quarter.

    The company blamed “softness in our retail channel stemming from heightened competition” in both Illinois and Massachusetts markets for the revenue dip.

    Still, CEO Andrew Thut previously tried to sound positive, saying the company was making progress on scaling production in Illinois, growing wholesale in Massachusetts and seeing better results in Washington.

    “Despite the uncertainties surrounding federal cannabis reform, we’re optimistic, especially given signs that we may have unexpected advocates in the incoming administration,” Thut said at the time. “We’re confident entering Q4 and are ready to return to growth and sustainable positive cash flows from operations.”

    4Front also said at the time that it retained Canaccord Genuity to help with an internal reorganization, particularly regarding its financial position. The company also took out an $850,000 loan to finance ongoing operations.

    The company asked for relief under Canadian National Policy 12-203, which would block management from trading company securities until it files its financials. The Ontario Securities Commission hasn’t ruled on this request yet.

    If rejected, the commission might instead impose a broader order affecting all company securities.

    While the filings remain outstanding, 4Front promised to provide biweekly status updates and confirmed that insiders can’t trade company stock until the annual filings are submitted.

    The company has been pushing growth initiatives despite its financial crunch. During the third quarter, it continued building a massive 250,000-square-foot cultivation facility in Matteson, Illinois, planning to expand from 24,000 to 34,800 square feet of growing space. Its Massachusetts wholesale business showed some promise with a 56% increase in revenue to nearly $2 million for the quarter.

    As of September 2024, 4Front had $278 million in assets, with just $1.2 million in cash, against $326.5 million in liabilities, including nearly $69 million in debt.

    The company said there are no bankruptcy proceedings underway and “no material business developments” since filing its last quarterly report in December beyond what its already disclosed.

    The post 4Front Ventures delays annual filings, can’t pay auditors appeared first on Green Market Report.

  • Florida’s marijuana patient base continues to grow as lawmakers target hemp industry

    Florida’s marijuana patient base continues to grow as lawmakers target hemp industry

    Florida’s medical marijuana registry continues to grow, adding roughly 14,000 patients in early 2025. That trend could continue as lawmakers target a key competitor for the industry, proposing tough new hemp rules that could reshape the state’s cannabis scene.

    Patient numbers rose steadily from 895,000 in January to 909,000 by April, according to the Florida Office of Medical Marijuana Use. Meanwhile, Florida senators unanimously backed legislation to restrict hemp-derived THC products, resembling a bill Gov. Ron DeSantis vetoed last year after hemp industry pressure, with some caveats.

    “We have retailers in the state of Florida that are selling products that are intoxicating,” the Florida Phoenix reported Republican Sen. Colleen Burton, the bill’s sponsor, as saying. “They are selling products that are putting adults and children in the hospital. And, sadly, they are selling products that are causing the deaths of Floridians.”

    Senate Bill 438 would ban Delta-8 products outright and limit Delta-9 hemp items to 5 milligrams per serving, according to the legislative text. THC-infused beverages would face the same cap and would only be allowed to be sold by businesses with liquor licenses, similar to legislation creeping its way through statehouses across the country.

    Recent testing of products from smoke shops across Florida found concerning potency issues: 50 of 53 hemp flower samples exceeded the federal 0.3% THC limit, making them essentially unregulated marijuana products, according to testimony during legislative hearings.

    “These are very intoxicating products,” Republican Sen. Gayle Harrell, who represent southeast Florida, said. “They’re addicting products at the end of the day. And people need to know that. … We need to make sure that people know what they’re buying. And we have seen so many fly-by-night places selling hemp – ‘safe hemp’ – and the THC levels are higher than the medical marijuana that you can get in a dispensary.”

    In some ways, hemp products have become a legitimate competitive threat for established cannabis companies. According to Viridian Capital Advisors, “It’s not exactly a closely held secret that hemp intoxicants, along with illicit THC vendors, have hit the THC industry right where it hurts.”

    Viridian’s report noted that analysts project “flat revenues for the top 12 MSOs for 2025″ while the hemp industry continues to grow due to price and convenience advantages. Consumers often “don’t care about seed-to-sale tracking and a (certificate of analysis) on every bottle. They will gladly trade that for the ability to purchase at their gas station or, better yet, online through the mail, especially if it costs less,” the Viridian report stated.

    That shift has pushed even major players like Curaleaf to hedge their bets. The international cannabis giant will open a hemp dispensary in Florida that will offer both its own Select brand and third-party hemp-derived THC beverages and edibles.

    “The move makes complete sense, going along with Curaleaf’s 2024 launch of the Hemp Company,” the Viridian analysis noted.

    But the political animosity around hemp regulation in the state remain complex. After DeSantis vetoed similar restrictions last year, a slew of hemp business owners donated to DeSantis’ efforts to defeat Amendment 3, which would have legalized recreational cannabis for adults aged 21 and above.

    Jacksonville Democratic Sen. Tracie Davis, who co-sponsored the bill, acknowledged during floor debate that the legislation wasn’t much different from last year’s vetoed version.

    If passed by the House and signed into law, the Department of Agriculture would handle enforcement with $2 million allocated to law enforcement for testing equipment.

    The bill also poses deeper questions about cannabis regulation frameworks. As Viridian framed it: “If cannabis is medicine, then perhaps it really should be heavily regulated by the FDA and heavily tested as well. But if cannabis is more analogous to wine or spirits, only less dangerous, then a whole other set of policy structures is appropriate.”

    The report points out: “You can easily walk into a liquor store and purchase enough Jack Daniels to kill five people, but nobody will question your right to make that purchase. Why potency or quantity limits for cannabis, which most people agree is less dangerous?”

    !function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”]){var e=document.querySelectorAll(“iframe”);for(var t in a.data[“datawrapper-height”])for(var r,i=0;r=e[i];i++)if(r.contentWindow===a.source){var d=a.data[“datawrapper-height”][t]+”px”;r.style.height=d}}}))}();

    The post Florida’s marijuana patient base continues to grow as lawmakers target hemp industry appeared first on Green Market Report.

  • Arizona marijuana market continues downward trend in February

    Arizona cannabis sales stats are down for the second straight year in a row, and have taken enough of a dip that the Arizona Mirror described medical marijuana sales as “cratering” and recreational sales as “softening.”

    According to sales figures from the state Department of Revenue, annual sales are down about 10% to $1.3 billion after three years of hitting at least $1.4 billion, according to analysis by the Mirror. And the downturn appears to have no end in sight.

    In February, the most recent month for which sales numbers are available, recreational and medical sales combined were just $96.3 million, down almost 15% year-over-year from $113 million. The most recent February numbers included $80.1 million in recreational sales and another $15.6 million in medical, with both figures down year-over-year, from $89.4 million and $23.6 million, respectively.

    Last year recreational marijuana sales were down by almost $43 million from 2023, the Mirror reported, while medical sales fell by $114 million between 2023 and 2024.

    The medical side of the industry in particular is “a shadow of what it was” just four years ago, the Mirror reported, with sales reaching just a third of what they used to be. Last year, total medical sales hit just $243 million, down from $733 million in 2021.

    The recreational market has continued to eclipse the medical side after launching in 2021, the Mirror noted, and comprised 81% of all cannabis sales last year, up from 66% in 2022.

    The post Arizona marijuana market continues downward trend in February appeared first on Green Market Report.

  • Missouri revokes 25 cannabis licenses in social equity program crackdown

    Missouri revokes 25 cannabis licenses in social equity program crackdown

    Missouri cannabis regulators revoked 25 more microbusiness licenses after concluding the operations wouldn’t be genuinely controlled by the disadvantaged entrepreneurs the program was designed to help, the Missouri Independent reported.

    The action brings to 34 the number of licenses canceled by the state since the social equity program launched in 2023, representing more than a third of the 96 permits issued through the lottery system, according to a news release from the Missouri Division of Cannabis Regulation on Monday.

    The microbusiness program was created to provide cannabis business opportunities for individuals who might otherwise lack access to the industry. However, regulators found evidence that well-connected investors and consultants were recruiting eligible individuals to apply but then arranging deals that limited their control and profits.

    “It is not sustainable to keep going through rounds of license issuance and then having to do rounds of revocations,” Amy Moore, director of the state’s cannabis regulatory division, said at a February town hall meeting, according to the Independent. “We’re never going to get this market fully built out.”

    The Independent, which has investigated the program for more than a year, reports that Arizona-based cannabis investor Michael Halow is connected to 22 of the revoked licenses, including 16 canceled Monday. Halow reportedly was associated with more than 700 of the approximately 3,600 applications submitted since the program began.

    In an email to the outlet, Halow disputed the state’s decision and plans to appeal. He defended his company’s approach, saying they help “people without generational wealth or experience as an entrepreneur” who open “businesses in neighborhoods in need of jobs and economic opportunity.”

    Four licenses connected to cannabis consultants David Brodsky and Scott Wootton were also revoked Monday. Regulators cited “false or misleading information” in their agreements that effectively transferred “ownership and operational control to another entity,” according to division documents referenced by the Independent. Brodsky and Wootton declined to comment to the outlet.

    The division announced new proposed rules in December aimed at preventing what it called “predatory arrangements in microbusiness licensing.” The state is currently reviewing public comments on these draft regulations before deciding when to submit finalized rules to the Missouri Secretary of State.

    The post Missouri revokes 25 cannabis licenses in social equity program crackdown appeared first on Green Market Report.

  • Hemp beverages beat craft beers when it comes to tariffs

    Hemp beverages beat craft beers when it comes to tariffs

    President Donald Trump’s on again, off again tariffs have rattled many industries, including the regulated cannabis industry that will be affected as vape hardware and packaging prices get hit with tariffs in shipments from Asia. But according to a new report from Whitney Economics, one segment could actually benefit: hemp beverages.

    While hemp beverages are sold in aluminum cans and will face increases in container costs from the tariffs, other parts of the supply chain are less affected by tariffs and the products are sold domestically. Add to that the surging popularity of the products, and you have a winning formula.

    Hemp drinks have hit the beverage industry by storm. Major distributors are stocking them even as states look to ban intoxicating hemp products. Some states are even carving out exceptions for the beverages in those proposed bans.

    Another advantage, according to Whitney Economics analyst Beau Whitney, is that all of this is happening as the craft beer business struggles. Alcohol consumption has been experiencing declines in sales, and the once-hot trend of craft beers is already looking like the moment is fading. The Brewers Association recorded 399 closures in 2024 compared to 335 new breweries, indicating a shift in the industry’s trajectory. The latest tariffs are adding another headache for those brewers.

    In addition to the aluminum used in cans, Whitney noted that beer companies also face tariffs on stainless steel, which is used in brewing equipment. Beer businesses are also dependent on hops, which are also tariffed.

    “On the other hand, the Trump tariffs could represent a significant upside opportunity for the hemp beverage industry, which has been experiencing strong growth for several years now,” wrote Whitney. “As alcohol and beer sales decline, hemp beverages have filled in the gaps in demand. The popularity of hemp cannabinoid beverages is just at the beginning of its ramp.”

    Whitney Economics noted that the hemp beverage sector has come on strong, especially since the market opened up in Minnesota in 2022.

    “Recent surveys in Texas, Illinois and Tennessee indicate that hemp beverages are capturing an increasing amount of market share among hemp retailers, distributors and manufacturers,” Whitney wrote in a recent newsletter.

    Hemp beverages tend to be more expensive than craft beers. A four-pack of infused seltzer can range from $9.99 to $16, while a 12-pack of craft beers often runs $20 or less. If the craft beer makers raise their prices in response to the increased expenses from tariffs, hemp beverages no longer look quite so expensive.

    So, while hemp beverages are fighting in various states to keep from getting banned, at least the group gets one gift in the form of avoiding most tariffs.

    The post Hemp beverages beat craft beers when it comes to tariffs appeared first on Green Market Report.

  • Scotts cuts Hawthorne Collective loose as it pivots away from cannabis

    Scotts cuts Hawthorne Collective loose as it pivots away from cannabis

    The Scotts Miracle-Gro Company (NYSE: SMG) made it official. The gardening behemoth has officially transferred its wholly-owned subsidiary, The Hawthorne Collective, Inc., to an independent strategic partner.

    Scotts established its hydroponic business, Hawthorne Gardening, to enter the cannabis space. In the beginning, it looked like a stellar plan, as the industry was rapidly growing and competing to see who could build the largest grow facilities. Sales of equipment soared and Hawthorne was seen as a leader in the space. The company also saw this as an opportunity to get into the investing side of cannabis as well and created the Hawthorne Collective as an investment vehicle.

    Riv Capital deal

    The company mentioned in its statement that the Hawthorne Collective’s holdings included investments in Fluent, previously Cansortium, a vertically integrated cannabis company with licenses and operations in Florida, Pennsylvania, Texas and New York. It did not remind investors that the company gave $150 million to Riv Capital in 2021. Then, in 2022, Hawthorne Collective gave Riv another $50 million and Riv Capital spent $247 million to buy New York medical operator Etain.

    The deal angered the Riv board, which felt it was too high a price to pay and that turned out to be prophetic. New York State delayed the company’s ability to sell adult-use cannabis, which pushed the investment return out by many years. Riv had paid $247 million for a company that was selling only a million dollars of medical marijuana a quarter.

    In December of 2024, Fluent bought Hawthorne Collective’s unsecured convertible notes in Riv for $160  million in Fluent stock.

    Hydroponic dries up

    Hawthorne Gardening fared no better. The bottom fell out as the commodity price for cannabis dropped below or at least close to what it cost to produce cannabis. Large multi-state operators began to scale back on the huge cultivation facilities and sales began to drop at Hawthorne Gardening. The falling fortunes at Hawthorne began to weigh on the overall company and were negatively impacting the company’s stock price.

    The board of directors decided it was time to part ways for both subsidiaries.

    “The Hawthorne Collective transaction is the initial step in our plan to move our cannabis-adjacent subsidiaries into a separate and independent company as we further our strategic focus on our core lawn and garden business,” said Jim Hagedorn, chairman and CEO of Scotts Miracle-Gro. “For our shareholders, this will reduce the impact of the cannabis sector’s volatility on our Company’s stock and provide opportunities to drive meaningful and immediate value creation through increased investments in our consumer business. As we further advance this plan, we next will look to separate The Hawthorne Gardening Company from ScottsMiracle-Gro by the close of fiscal 2025.

    According to the company statement, Scotts Miracle-Gro transferred The Hawthorne Collective to a strategic partner in exchange for an interest-bearing promissory note. Scotts said it retains an option to buy back The Hawthorne Collective or its assets should cannabis legalization and other measures to positively impact the industry be approved at the federal level.

    Hagedorn continued, saying, “The Hawthorne companies were intended to capitalize on the legal cannabis sector, but the ability to achieve sustained growth within this industry has been challenged by four years of unkept promises resulting in total inaction at the federal level on cannabis-related issues.”

    The post Scotts cuts Hawthorne Collective loose as it pivots away from cannabis appeared first on Green Market Report.

  • New Mexico governor signs off on Medical Psilocybin Act

    New Mexico governor signs off on Medical Psilocybin Act

    New Mexico Gov. Michelle Lujan Grisham signed the Medical Psilocybin Act, making it the third state in the country to legalize access to psilocybin.

    Green Market Report had previously written that S.B. 219, also known as the Medical Psilocybin Act, was approved with bipartisan veto-proof majorities in both chambers of the state…

    Please login to read all 443 words.